USA flag logo/image

An Official Website of the United States Government

Development of rapid detection tests for B pseudomallei

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
75895
Program Year/Program:
2005 / SBIR
Agency Tracking Number:
AI066647
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2005
Title: Development of rapid detection tests for B pseudomallei
Agency: HHS
Contract: 1R43AI066647-01
Award Amount: $975,862.00
 

Abstract:

DESCRIPTION (provided by applicant): The Gram negative bacterium Burkholderia pseudomallei causes human melioidosis, a rapidly progressing and frequently fatal disease if not treated early. It is endemic in areas of NE Thailand, Southeast Asia and northern parts of Australia and is listed as a Category B agent of potential bioterrorist threats. Antibiotic treatment is difficult and prolonged with significant relapse rates and there is currently no vaccine available for protection of naturally or intentionally exposed individuals. Accurate tests for the rapid detection of this organism in blood samples and other clinical materials are needed to guide the critical early phases of clinical management but are not currently available. It is the purpose of this application to identify antigens specific to B. pseudomallei and use these to generate monoclonal antibodies for inclusion in a rapid field test for antigen detection particularly in acute infections. In addition, these antigens can be used directly to develop specific immunoblots for evaluating antibody responses in acute and chronic phases of disease. To achieve these goals, InBios (experienced in commercial development of rapid diagnostic assays) has brought together a team of experts in the UK with access to an animal model system for melioidosis with a group in Northeastern Thailand with access to clinical samples enabling Phase 1 field testing of the prototype assays produced. These tools will be invaluable in detecting and monitoring acute and chronic B. pseudomallei infections both in endemic areas as well as following a bioterrorist attack.

Principal Investigator:

Raymond Houghton
2063445821
raymond@inbios.com

Business Contact:


2063445821
Small Business Information at Submission:

Inbios International, Inc.
562 1St Ave. South, Suite 600 Seattle, WA 98104

EIN/Tax ID: 911791824
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No